Should we also evaluate SET together with CIP2A for the treatment with second-generation tyrosine kinase inhibitors in chronic myeloid leukemia?

Leukemia. 2015 Oct;29(10):2117. doi: 10.1038/leu.2015.201. Epub 2015 Aug 18.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Autoantigens
  • DNA-Binding Proteins
  • Evaluation Studies as Topic
  • Histone Chaperones / antagonists & inhibitors*
  • Humans
  • Intracellular Signaling Peptides and Proteins
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / enzymology*
  • Membrane Proteins / antagonists & inhibitors*
  • Prognosis
  • Protein Kinase Inhibitors / therapeutic use*
  • Protein-Tyrosine Kinases / antagonists & inhibitors*
  • Transcription Factors / antagonists & inhibitors*

Substances

  • Autoantigens
  • CIP2A protein, human
  • DNA-Binding Proteins
  • Histone Chaperones
  • Intracellular Signaling Peptides and Proteins
  • Membrane Proteins
  • Protein Kinase Inhibitors
  • SET protein, human
  • Transcription Factors
  • Protein-Tyrosine Kinases